{"name":"Centers for Disease Control and Prevention","slug":"centers-for-disease-control-and-prevention","ticker":"","exchange":"","domain":"cdc.gov","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":30,"colorKey":"oncology","drugs":[{"name":"23-valent polysaccharide vaccine","genericName":"23-valent polysaccharide vaccine","slug":"23-valent-polysaccharide-vaccine","indication":"Other","status":"phase_1"},{"name":"Anthrax Vaccine Adsorbed","genericName":"Anthrax Vaccine Adsorbed","slug":"anthrax-vaccine-adsorbed","indication":"Other","status":"marketed"},{"name":"Flublok™ Quadrivalent by Sanofi, Inc.","genericName":"Flublok™ Quadrivalent by Sanofi, Inc.","slug":"flublok-quadrivalent-by-sanofi-inc","indication":"Seasonal influenza prevention in adults 18 years of age and older","status":"marketed"},{"name":"IPV at 14 and 22 weeks of age, RotaTeq","genericName":"IPV at 14 and 22 weeks of age, RotaTeq","slug":"ipv-at-14-and-22-weeks-of-age-rotateq","indication":"Other","status":"marketed"},{"name":"IPV at 14 and 22 weeks of age, Rotarix","genericName":"IPV at 14 and 22 weeks of age, Rotarix","slug":"ipv-at-14-and-22-weeks-of-age-rotarix","indication":"Prevention of poliomyelitis (IPV component)","status":"marketed"},{"name":"IPV at 6 and fIPV at 22 weeks, Rotarix","genericName":"IPV at 6 and fIPV at 22 weeks, Rotarix","slug":"ipv-at-6-and-fipv-at-22-weeks-rotarix","indication":"Prevention of poliomyelitis (poliovirus types 1, 2, and 3)","status":"marketed"},{"name":"JYNNEOS (Liquid Formulation)","genericName":"JYNNEOS (Liquid Formulation)","slug":"jynneos-liquid-formulation","indication":"Prevention of monkeypox (mpox) in adults at risk of exposure","status":"phase_3"},{"name":"Nuvaring","genericName":"Nuvaring","slug":"nuvaring","indication":"Other","status":"marketed"},{"name":"bOPV (two dose)","genericName":"bOPV (two dose)","slug":"bopv-two-dose","indication":"Prevention of poliomyelitis caused by poliovirus types 1 and 3","status":"marketed"},{"name":"doxyxcycline","genericName":"doxyxcycline","slug":"doxyxcycline","indication":"Other","status":"phase_2"},{"name":"fIPV (0.1mL) IM","genericName":"fIPV (0.1mL) IM","slug":"fipv-0-1ml-im","indication":"Prevention of poliomyelitis (polio) caused by poliovirus types 1, 2, and 3","status":"marketed"},{"name":"fIPV (0.2mL) IM","genericName":"fIPV (0.2mL) IM","slug":"fipv-0-2ml-im","indication":"Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3","status":"marketed"},{"name":"fIPV at 6-14-22 weeks of age, Rotarix","genericName":"fIPV at 6-14-22 weeks of age, Rotarix","slug":"fipv-at-6-14-22-weeks-of-age-rotarix","indication":"Prevention of poliomyelitis (fIPV component)","status":"marketed"},{"name":"Arm E: f-IPV and bOPV","genericName":"Arm E: f-IPV and bOPV","slug":"arm-e-f-ipv-and-bopv","indication":"Poliomyelitis prevention in infants and children","status":"phase_3"},{"name":"FLUAD Quadrivalent","genericName":"FLUAD Quadrivalent","slug":"fluad-quadrivalent","indication":"Seasonal influenza prevention in adults and children ≥6 months of age","status":"marketed"},{"name":"FluQuadri","genericName":"FluQuadri","slug":"fluquadri","indication":"Seasonal influenza prevention in adults and children","status":"phase_3"},{"name":"IPV at 14 and fIPV at 22 weeks, RotaTeq","genericName":"IPV at 14 and fIPV at 22 weeks, RotaTeq","slug":"ipv-at-14-and-fipv-at-22-weeks-rotateq","indication":"Prevention of poliomyelitis (IPV component)","status":"marketed"},{"name":"IPV at 14 and fIPV at 22 weeks, Rotarix","genericName":"IPV at 14 and fIPV at 22 weeks, Rotarix","slug":"ipv-at-14-and-fipv-at-22-weeks-rotarix","indication":"Other","status":"marketed"},{"name":"IPV at 6 and fIPV at 22 weeks, RotaTeq","genericName":"IPV at 6 and fIPV at 22 weeks, RotaTeq","slug":"ipv-at-6-and-fipv-at-22-weeks-rotateq","indication":"Other","status":"marketed"},{"name":"Sabin IPV","genericName":"Sabin IPV","slug":"sabin-ipv","indication":"Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3","status":"marketed"},{"name":"VaxigripTetra™ by Sanofi, Inc.","genericName":"VaxigripTetra™ by Sanofi, Inc.","slug":"vaxigriptetra-by-sanofi-inc","indication":"Seasonal influenza prevention in adults and children ≥6 months of age","status":"marketed"},{"name":"Yellow Fever 17DD Vaccine","genericName":"Yellow Fever 17DD Vaccine","slug":"yellow-fever-17dd-vaccine","indication":"Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas","status":"marketed"},{"name":"amodiaquine plus artesunate","genericName":"amodiaquine plus artesunate","slug":"amodiaquine-plus-artesunate","indication":"Other","status":"marketed"},{"name":"bOPV (three dose)","genericName":"bOPV (three dose)","slug":"bopv-three-dose","indication":"Prevention of poliomyelitis caused by poliovirus types 1 and 3","status":"marketed"},{"name":"bOPV/IPV (14 weeks)","genericName":"bOPV/IPV (14 weeks)","slug":"bopv-ipv-14-weeks","indication":"Protection against poliovirus and influenza in individuals 6 weeks of age and older","status":"phase_3"},{"name":"bOPV/IPV (6 weeks)","genericName":"bOPV/IPV (6 weeks)","slug":"bopv-ipv-6-weeks","indication":"Protection against poliovirus and Haemophilus influenzae type b in infants and young children","status":"phase_3"},{"name":"fIPV at 6-14-22 weeks of age, RotaTeq","genericName":"fIPV at 6-14-22 weeks of age, RotaTeq","slug":"fipv-at-6-14-22-weeks-of-age-rotateq","indication":"Other","status":"marketed"},{"name":"mOPV2 at 6 and 10 weeks of age","genericName":"mOPV2 at 6 and 10 weeks of age","slug":"mopv2-at-6-and-10-weeks-of-age","indication":"Other","status":"marketed"},{"name":"mOPV2 at 6 and 7 weeks of age","genericName":"mOPV2 at 6 and 7 weeks of age","slug":"mopv2-at-6-and-7-weeks-of-age","indication":"Prevention of poliomyelitis caused by poliovirus type 2 in infants","status":"marketed"},{"name":"mOPV2 at 6 and 8 weeks of age","genericName":"mOPV2 at 6 and 8 weeks of age","slug":"mopv2-at-6-and-8-weeks-of-age","indication":"Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"immunology","drugs":[{"name":"Amodiaquine-artesunate (ASAQ)","genericName":"Amodiaquine-artesunate (ASAQ)","slug":"amodiaquine-artesunate-asaq","indication":"Uncomplicated malaria caused by Plasmodium falciparum","status":"marketed"},{"name":"AQAS","genericName":"AQAS","slug":"aqas","indication":"Laboratory quality assurance for HIV testing","status":"marketed"},{"name":"Artemether+Lumefantrine (AL)","genericName":"Artemether+Lumefantrine (AL)","slug":"artemether-lumefantrine-al","indication":"Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi","status":"marketed"},{"name":"Artemether-lumefantrine: P. falciparum","genericName":"Artemether-lumefantrine: P. falciparum","slug":"artemether-lumefantrine-p-falciparum","indication":"Uncomplicated Plasmodium falciparum malaria","status":"phase_1"},{"name":"Infant nevirapine","genericName":"Infant nevirapine","slug":"infant-nevirapine","indication":"Prevention of mother-to-child transmission of HIV in infants","status":"phase_3"},{"name":"Intradermal vaccine","genericName":"Intradermal vaccine","slug":"intradermal-vaccine","indication":"Influenza prevention (intradermal formulations)","status":"marketed"},{"name":"Maternal zidovudine/lamivudine/lopinavir-ritonavir","genericName":"Maternal zidovudine/lamivudine/lopinavir-ritonavir","slug":"maternal-zidovudine-lamivudine-lopinavir-ritonavir","indication":"Prevention of mother-to-child HIV transmission in pregnant women","status":"phase_3"},{"name":"Mefloquine- Artesunate","genericName":"Mefloquine- Artesunate","slug":"mefloquine-artesunate","indication":"Malaria (uncomplicated and severe)","status":"marketed"},{"name":"amodiaquine plus sulfadoxine-pyrimethamine","genericName":"amodiaquine plus sulfadoxine-pyrimethamine","slug":"amodiaquine-plus-sulfadoxine-pyrimethamine","indication":"Malaria (uncomplicated Plasmodium falciparum)","status":"marketed"},{"name":"bOPV/IPV (6 & 14 weeks)","genericName":"bOPV/IPV (6 & 14 weeks)","slug":"bopv-ipv-6-14-weeks","indication":"Protection against poliovirus and Haemophilus influenzae type b infections","status":"phase_3"},{"name":"chlorproguanil-dapsone plus artesunate","genericName":"chlorproguanil-dapsone plus artesunate","slug":"chlorproguanil-dapsone-plus-artesunate","indication":"Uncomplicated malaria caused by Plasmodium falciparum","status":"marketed"},{"name":"lumefantrine plus artemether","genericName":"lumefantrine plus artemether","slug":"lumefantrine-plus-artemether","indication":"Uncomplicated malaria caused by Plasmodium falciparum","status":"marketed"},{"name":"lumefantrine-artemether","genericName":"lumefantrine-artemether","slug":"lumefantrine-artemether","indication":"Uncomplicated malaria caused by Plasmodium falciparum","status":"marketed"},{"name":"rifapentine and moxifloxacin","genericName":"rifapentine and moxifloxacin","slug":"rifapentine-and-moxifloxacin","indication":"Treatment of latent tuberculosis infection","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"Group C: Inactivated Polio Vaccine","genericName":"Group C: Inactivated Polio Vaccine","slug":"group-c-inactivated-polio-vaccine","indication":"Poliomyelitis prevention","status":"phase_3"},{"name":"fIPV (0.1 mL) ID","genericName":"fIPV (0.1 mL) ID","slug":"fipv-0-1-ml-id","indication":"Poliomyelitis prevention in outbreak response and immunization campaigns","status":"marketed"},{"name":"IPV at 6 weeks of age","genericName":"IPV at 6 weeks of age","slug":"ipv-at-6-weeks-of-age","indication":"Prevention of poliomyelitis in infants and children","status":"marketed"},{"name":"Sulfadoxine-pyrimethamine/folic acid","genericName":"Sulfadoxine-pyrimethamine/folic acid","slug":"sulfadoxine-pyrimethamine-folic-acid","indication":"Malaria prophylaxis and treatment (Plasmodium falciparum)","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"REZ","genericName":"REZ","slug":"rez","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"marketed"}]}],"pipeline":[{"name":"23-valent polysaccharide vaccine","genericName":"23-valent polysaccharide vaccine","slug":"23-valent-polysaccharide-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Amodiaquine-artesunate (ASAQ)","genericName":"Amodiaquine-artesunate (ASAQ)","slug":"amodiaquine-artesunate-asaq","phase":"marketed","mechanism":"ASAQ is a fixed-dose combination of amodiaquine (a 4-aminoquinoline) and artesunate (an artemisinin derivative) that kills malaria parasites through complementary mechanisms involving heme detoxification disruption and rapid parasite clearance.","indications":["Uncomplicated malaria caused by Plasmodium falciparum","Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae"],"catalyst":""},{"name":"Anthrax Vaccine Adsorbed","genericName":"Anthrax Vaccine Adsorbed","slug":"anthrax-vaccine-adsorbed","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Flublok™ Quadrivalent by Sanofi, Inc.","genericName":"Flublok™ Quadrivalent by Sanofi, Inc.","slug":"flublok-quadrivalent-by-sanofi-inc","phase":"marketed","mechanism":"Flublok Quadrivalent is an inactivated influenza vaccine produced using recombinant DNA technology that stimulates the immune system to produce antibodies against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults 18 years of age and older"],"catalyst":""},{"name":"Group C: Inactivated Polio Vaccine","genericName":"Group C: Inactivated Polio Vaccine","slug":"group-c-inactivated-polio-vaccine","phase":"phase_3","mechanism":"Inactivated Polio Vaccine stimulates the immune system to produce antibodies against poliovirus by introducing chemically inactivated (killed) virus particles.","indications":["Poliomyelitis prevention","Routine childhood immunization against poliovirus types 1, 2, and 3"],"catalyst":""},{"name":"IPV at 14 and 22 weeks of age, RotaTeq","genericName":"IPV at 14 and 22 weeks of age, RotaTeq","slug":"ipv-at-14-and-22-weeks-of-age-rotateq","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IPV at 14 and 22 weeks of age, Rotarix","genericName":"IPV at 14 and 22 weeks of age, Rotarix","slug":"ipv-at-14-and-22-weeks-of-age-rotarix","phase":"marketed","mechanism":"IPV (inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.","indications":["Prevention of poliomyelitis (IPV component)","Prevention of rotavirus gastroenteritis (Rotarix component)"],"catalyst":""},{"name":"IPV at 6 and fIPV at 22 weeks, Rotarix","genericName":"IPV at 6 and fIPV at 22 weeks, Rotarix","slug":"ipv-at-6-and-fipv-at-22-weeks-rotarix","phase":"marketed","mechanism":"IPV (inactivated poliovirus vaccine) and fIPV (fractional dose IPV) stimulate immune responses against poliovirus types 1, 2, and 3, while Rotarix protects against rotavirus infection through live attenuated viral immunization.","indications":["Prevention of poliomyelitis (poliovirus types 1, 2, and 3)","Prevention of rotavirus gastroenteritis"],"catalyst":""},{"name":"JYNNEOS (Liquid Formulation)","genericName":"JYNNEOS (Liquid Formulation)","slug":"jynneos-liquid-formulation","phase":"phase_3","mechanism":"JYNNEOS is a live attenuated vaccinia virus vaccine that stimulates immune responses against orthopoxviruses, including monkeypox and smallpox.","indications":["Prevention of monkeypox (mpox) in adults at risk of exposure","Prevention of smallpox in at-risk populations"],"catalyst":""},{"name":"Nuvaring","genericName":"Nuvaring","slug":"nuvaring","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"bOPV (two dose)","genericName":"bOPV (two dose)","slug":"bopv-two-dose","phase":"marketed","mechanism":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.","indications":["Prevention of poliomyelitis caused by poliovirus types 1 and 3"],"catalyst":""},{"name":"doxyxcycline","genericName":"doxyxcycline","slug":"doxyxcycline","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"fIPV (0.1 mL) ID","genericName":"fIPV (0.1 mL) ID","slug":"fipv-0-1-ml-id","phase":"marketed","mechanism":"fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.","indications":["Poliomyelitis prevention in outbreak response and immunization campaigns","Polio vaccination in resource-limited settings using fractional dosing"],"catalyst":""},{"name":"fIPV (0.1mL) IM","genericName":"fIPV (0.1mL) IM","slug":"fipv-0-1ml-im","phase":"marketed","mechanism":"fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.","indications":["Prevention of poliomyelitis (polio) caused by poliovirus types 1, 2, and 3"],"catalyst":""},{"name":"fIPV (0.2mL) IM","genericName":"fIPV (0.2mL) IM","slug":"fipv-0-2ml-im","phase":"marketed","mechanism":"fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection.","indications":["Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3"],"catalyst":""},{"name":"fIPV at 6-14-22 weeks of age, Rotarix","genericName":"fIPV at 6-14-22 weeks of age, Rotarix","slug":"fipv-at-6-14-22-weeks-of-age-rotarix","phase":"marketed","mechanism":"fIPV (fractional-dose inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies against poliovirus and rotavirus, respectively, preventing infection and disease.","indications":["Prevention of poliomyelitis (fIPV component)","Prevention of rotavirus gastroenteritis (Rotarix component)"],"catalyst":""},{"name":"AQAS","genericName":"AQAS","slug":"aqas","phase":"marketed","mechanism":"AQAS is a quality assurance system used by the CDC to monitor and ensure the accuracy of laboratory test results for infectious diseases.","indications":["Laboratory quality assurance for HIV testing","Proficiency testing for infectious disease diagnostics"],"catalyst":""},{"name":"Arm E: f-IPV and bOPV","genericName":"Arm E: f-IPV and bOPV","slug":"arm-e-f-ipv-and-bopv","phase":"phase_3","mechanism":"f-IPV and bOPV are inactivated and bivalent oral polio vaccines that stimulate immune responses against poliovirus types to prevent poliomyelitis infection.","indications":["Poliomyelitis prevention in infants and children"],"catalyst":""},{"name":"Artemether+Lumefantrine (AL)","genericName":"Artemether+Lumefantrine (AL)","slug":"artemether-lumefantrine-al","phase":"marketed","mechanism":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage.","indications":["Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi","Malaria treatment in endemic regions"],"catalyst":""},{"name":"Artemether-lumefantrine: P. falciparum","genericName":"Artemether-lumefantrine: P. falciparum","slug":"artemether-lumefantrine-p-falciparum","phase":"phase_1","mechanism":"Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway.","indications":["Uncomplicated Plasmodium falciparum malaria"],"catalyst":""},{"name":"FLUAD Quadrivalent","genericName":"FLUAD Quadrivalent","slug":"fluad-quadrivalent","phase":"marketed","mechanism":"FLUAD Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children ≥6 months of age"],"catalyst":""},{"name":"FluQuadri","genericName":"FluQuadri","slug":"fluquadri","phase":"phase_3","mechanism":"FluQuadri is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children"],"catalyst":""},{"name":"IPV at 14 and fIPV at 22 weeks, RotaTeq","genericName":"IPV at 14 and fIPV at 22 weeks, RotaTeq","slug":"ipv-at-14-and-fipv-at-22-weeks-rotateq","phase":"marketed","mechanism":"IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.","indications":["Prevention of poliomyelitis (IPV component)","Prevention of rotavirus gastroenteritis (RotaTeq component)"],"catalyst":""},{"name":"IPV at 14 and fIPV at 22 weeks, Rotarix","genericName":"IPV at 14 and fIPV at 22 weeks, Rotarix","slug":"ipv-at-14-and-fipv-at-22-weeks-rotarix","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IPV at 6 and fIPV at 22 weeks, RotaTeq","genericName":"IPV at 6 and fIPV at 22 weeks, RotaTeq","slug":"ipv-at-6-and-fipv-at-22-weeks-rotateq","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IPV at 6 weeks of age","genericName":"IPV at 6 weeks of age","slug":"ipv-at-6-weeks-of-age","phase":"marketed","mechanism":"IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles.","indications":["Prevention of poliomyelitis in infants and children","Routine immunization at 6 weeks of age as part of childhood vaccination schedule"],"catalyst":""},{"name":"Infant nevirapine","genericName":"Infant nevirapine","slug":"infant-nevirapine","phase":"phase_3","mechanism":"Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication in infants.","indications":["Prevention of mother-to-child transmission of HIV in infants","HIV-1 infection in infants and children"],"catalyst":""},{"name":"Intradermal vaccine","genericName":"Intradermal vaccine","slug":"intradermal-vaccine","phase":"marketed","mechanism":"Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration.","indications":["Influenza prevention (intradermal formulations)","Tuberculosis prevention (BCG and experimental TB vaccines)","Other infectious diseases via intradermal route (varies by specific vaccine)"],"catalyst":""},{"name":"Maternal zidovudine/lamivudine/lopinavir-ritonavir","genericName":"Maternal zidovudine/lamivudine/lopinavir-ritonavir","slug":"maternal-zidovudine-lamivudine-lopinavir-ritonavir","phase":"phase_3","mechanism":"This combination of antiretroviral drugs inhibits HIV reverse transcriptase and protease to suppress viral replication in pregnant women and prevent mother-to-child transmission.","indications":["Prevention of mother-to-child HIV transmission in pregnant women","HIV infection in pregnancy"],"catalyst":""},{"name":"Mefloquine- Artesunate","genericName":"Mefloquine- Artesunate","slug":"mefloquine-artesunate","phase":"marketed","mechanism":"Mefloquine and artesunate work synergistically to kill malaria parasites through distinct mechanisms: mefloquine disrupts parasite membrane function while artesunate generates reactive oxygen species that damage parasite proteins and DNA.","indications":["Malaria (uncomplicated and severe)","Drug-resistant malaria"],"catalyst":""},{"name":"REZ","genericName":"REZ","slug":"rez","phase":"marketed","mechanism":"REZ is a monoclonal antibody that targets the CD19 protein on B cells.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Relapsed or refractory follicular lymphoma","Relapsed or refractory mantle cell lymphoma"],"catalyst":""},{"name":"Sabin IPV","genericName":"Sabin IPV","slug":"sabin-ipv","phase":"marketed","mechanism":"Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.","indications":["Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3"],"catalyst":""},{"name":"Sulfadoxine-pyrimethamine/folic acid","genericName":"Sulfadoxine-pyrimethamine/folic acid","slug":"sulfadoxine-pyrimethamine-folic-acid","phase":"marketed","mechanism":"Sulfadoxine-pyrimethamine inhibits dihydrofolate reductase and dihydropteroate synthase in parasites, blocking folate synthesis, while folic acid supplementation protects human cells from toxicity.","indications":["Malaria prophylaxis and treatment (Plasmodium falciparum)","Toxoplasmosis prophylaxis and treatment in immunocompromised patients"],"catalyst":""},{"name":"VaxigripTetra™ by Sanofi, Inc.","genericName":"VaxigripTetra™ by Sanofi, Inc.","slug":"vaxigriptetra-by-sanofi-inc","phase":"marketed","mechanism":"VaxigripTetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.","indications":["Seasonal influenza prevention in adults and children ≥6 months of age"],"catalyst":""},{"name":"Yellow Fever 17DD Vaccine","genericName":"Yellow Fever 17DD Vaccine","slug":"yellow-fever-17dd-vaccine","phase":"marketed","mechanism":"The Yellow Fever 17DD vaccine stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus by using a live attenuated (weakened) viral strain.","indications":["Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas"],"catalyst":""},{"name":"amodiaquine plus artesunate","genericName":"amodiaquine plus artesunate","slug":"amodiaquine-plus-artesunate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"amodiaquine plus sulfadoxine-pyrimethamine","genericName":"amodiaquine plus sulfadoxine-pyrimethamine","slug":"amodiaquine-plus-sulfadoxine-pyrimethamine","phase":"marketed","mechanism":"This combination inhibits parasite DNA synthesis and folate metabolism through complementary antimalarial mechanisms.","indications":["Malaria (uncomplicated Plasmodium falciparum)","Malaria treatment in areas with chloroquine and sulfadoxine-pyrimethamine resistance"],"catalyst":""},{"name":"bOPV (three dose)","genericName":"bOPV (three dose)","slug":"bopv-three-dose","phase":"marketed","mechanism":"bOPV (bivalent oral polio vaccine) stimulates the immune system to produce antibodies against poliovirus types 1 and 3, providing protection against poliomyelitis.","indications":["Prevention of poliomyelitis caused by poliovirus types 1 and 3"],"catalyst":""},{"name":"bOPV/IPV (14 weeks)","genericName":"bOPV/IPV (14 weeks)","slug":"bopv-ipv-14-weeks","phase":"phase_3","mechanism":"bOPV/IPV is a vaccine that stimulates the body's immune response to protect against poliovirus and influenza.","indications":["Protection against poliovirus and influenza in individuals 6 weeks of age and older","Prevention of polio and influenza in individuals 14 weeks of age and older"],"catalyst":""},{"name":"bOPV/IPV (6 & 14 weeks)","genericName":"bOPV/IPV (6 & 14 weeks)","slug":"bopv-ipv-6-14-weeks","phase":"phase_3","mechanism":"bOPV/IPV vaccine stimulates the body's immune response to produce antibodies against poliovirus and Haemophilus influenzae type b.","indications":["Protection against poliovirus and Haemophilus influenzae type b infections"],"catalyst":""},{"name":"bOPV/IPV (6 weeks)","genericName":"bOPV/IPV (6 weeks)","slug":"bopv-ipv-6-weeks","phase":"phase_3","mechanism":"bOPV/IPV is a vaccine that stimulates the body's immune response to protect against poliovirus and Haemophilus influenzae type b.","indications":["Protection against poliovirus and Haemophilus influenzae type b in infants and young children","Prevention of polio and Hib disease in individuals who have not previously been vaccinated or have not completed a full vaccination series"],"catalyst":""},{"name":"chlorproguanil-dapsone plus artesunate","genericName":"chlorproguanil-dapsone plus artesunate","slug":"chlorproguanil-dapsone-plus-artesunate","phase":"marketed","mechanism":"This combination antimalarial drug works by inhibiting parasite dihydrofolate reductase (via chlorproguanil and dapsone) and disrupting mitochondrial function (via artesunate) to kill Plasmodium parasites through multiple pathways.","indications":["Uncomplicated malaria caused by Plasmodium falciparum","Malaria treatment in areas with drug-resistant parasites"],"catalyst":""},{"name":"fIPV at 6-14-22 weeks of age, RotaTeq","genericName":"fIPV at 6-14-22 weeks of age, RotaTeq","slug":"fipv-at-6-14-22-weeks-of-age-rotateq","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"lumefantrine plus artemether","genericName":"lumefantrine plus artemether","slug":"lumefantrine-plus-artemether","phase":"marketed","mechanism":"Lumefantrine and artemether work together as antimalarial agents that kill malaria parasites through distinct mechanisms involving heme detoxification and rapid parasite clearance.","indications":["Uncomplicated malaria caused by Plasmodium falciparum","Malaria caused by other Plasmodium species susceptible to artemether-lumefantrine"],"catalyst":""},{"name":"lumefantrine-artemether","genericName":"lumefantrine-artemether","slug":"lumefantrine-artemether","phase":"marketed","mechanism":"Lumefantrine and artemether are antimalarial agents that work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and generating reactive oxygen species.","indications":["Uncomplicated malaria caused by Plasmodium falciparum","Malaria caused by Plasmodium vivax, ovale, and malariae"],"catalyst":""},{"name":"mOPV2 at 6 and 10 weeks of age","genericName":"mOPV2 at 6 and 10 weeks of age","slug":"mopv2-at-6-and-10-weeks-of-age","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"mOPV2 at 6 and 7 weeks of age","genericName":"mOPV2 at 6 and 7 weeks of age","slug":"mopv2-at-6-and-7-weeks-of-age","phase":"marketed","mechanism":"mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.","indications":["Prevention of poliomyelitis caused by poliovirus type 2 in infants"],"catalyst":""},{"name":"mOPV2 at 6 and 8 weeks of age","genericName":"mOPV2 at 6 and 8 weeks of age","slug":"mopv2-at-6-and-8-weeks-of-age","phase":"marketed","mechanism":"mOPV2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 to prevent poliomyelitis infection.","indications":["Prevention of poliomyelitis caused by poliovirus type 2 in infants at 6 and 8 weeks of age"],"catalyst":""},{"name":"rifapentine and moxifloxacin","genericName":"rifapentine and moxifloxacin","slug":"rifapentine-and-moxifloxacin","phase":"phase_3","mechanism":"Rifapentine is a bactericidal antibiotic that inhibits DNA-dependent RNA polymerase, while moxifloxacin is a bactericidal antibiotic that inhibits DNA gyrase and topoisomerase IV.","indications":["Treatment of latent tuberculosis infection","Treatment of active tuberculosis disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPeExfc1RpZTZES09zNTgxR3NCa3IwZVIwM3hDRktqN2RXeWRiSnRmWnAtdlVYLTBXM3R3REJsLUQ5ZHEwd1BreVdzRFA0dWdIR1M0TXJKQ3JLYTJDakNOTlNXcTNmMlRjeDA3TVlreUxxRkhUYzgtaUNBcG01MXJqb3EtVmtpMm1zUHpJX05sY1A0TnQ1RjdMNS0tb2VPbkRaTDd3?oc=5","date":"2026-04-07","type":"pipeline","source":"The Pharma Letter","summary":"RFK Jr seeks apparent workaround on CDC vaccine committee - The Pharma Letter","headline":"RFK Jr seeks apparent workaround on CDC vaccine committee","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOdm5uTE9mdWZxZkNYUXRkdUNwbnQ3bXBzcU55MXNjYndTSDRPOG9LdzZKTGJRM0U3eGVxLU02STZHbnN6cHFhYzh5bWN0SFluRVpUM0tzWnZ0NFBZdFc4R2x5dmtoWVlWSVVLa00zc0J4N292cW5aUjZvQkJJTENDc1p0eWg3UklMaHZIMmlqdmY5MG5ieGU5RHlEU0x3Z2pEdkdqZW1NQ1JaalhZcE1Md3dCT1IyODYyMHo0eHotbHdraC1xbk5WMkpB?oc=5","date":"2026-03-03","type":"pipeline","source":"Reuters","summary":"CDC acting director Bhattacharya urges use of measles vaccine - Reuters","headline":"CDC acting director Bhattacharya urges use of measles vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNWEJMNkF4YWhhWnp1cy0weGdrSGl1SGZHMmVoeGNsRzFmYTlFTG14YW10STFkNGppZldqaE1aOFJReGxRdFJuY3NsR3lHanhUeHVVdnUwcHZWMHFybkR1MVJ6a0Q3SFEzVEpnNUVTTVFqdnNETXlETGt2ODdJVkdDOUVFdXl1czNHLS16NVVzYnBPQ3A4ZEY2UDRUTGtjdnc?oc=5","date":"2026-02-19","type":"pipeline","source":"Fierce Pharma","summary":"Amid CDC upheaval, key vaccine panel won't convene February meeting - Fierce Pharma","headline":"Amid CDC upheaval, key vaccine panel won't convene February meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPVldTMzN6TmN6LUk2Sl9jZzYyZnJEd19KY1pBa3BwbEd4dnFhLWd4bVg3Y1ZxUFZxVXNmM2dPTV9jQzhIb2xSaHVCbTJ3QWh2TXRoRWdvQ0Z1TG9SN24xeGRBWFlBZGh0THBCZXpJbmtpRE0zaE90dkdzSFRaZUo3WTl5SEQ2cVROU3I5MVNYOEdjZGJrRDFuVU92S1pOa0tIdW0xVEoySVhPQ3pXMjR4dUhmRUdRUlE0dGpFMnllWXk2NXIzWmc?oc=5","date":"2026-02-19","type":"pipeline","source":"Reuters","summary":"US NIH director Bhattacharya to temporarily run CDC - Reuters","headline":"US NIH director Bhattacharya to temporarily run CDC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQY0dldnc0X3FkWWVZSVBCaTY2TmRvZ1QyZzZ5NWlMbTVrUkVvRThMOHh2TTBTcWhHbVNkOThzeEh4Z25FeTdfMmktdFNkUlJTbkpYSWotSHg4ejllMkhGYXp3SFM5MkpKSEEwcG13cHIzYWpBREVPQjlZOGMzWnd5RkpTUkxoWWxNZHFOMVFJczV5aHc4by1yZDNGUXZxbmVmMGlSbQ?oc=5","date":"2026-02-11","type":"pipeline","source":"BioPharma Dive","summary":"CDC moves to cut $600M in grants to Democrat-led states - BioPharma Dive","headline":"CDC moves to cut $600M in grants to Democrat-led states","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE84RC1KMzR2bDZKbXp6QmhOYWhVZzExeU1pdERaR3lqOTh2SFhUam44TWg5b241RDBxb1ZYT3pud2JyS0Z6a2I2d29aUnBuN3ZfMjV4bklfTFQtNUJrWkJNdEY5VjdfVEhBbVBxdkVQV01UVDlKRllXM0kzZ00?oc=5","date":"2026-01-07","type":"pipeline","source":"Centers for Disease Control and Prevention | CDC (.gov)","summary":"2025 – 2026 Clinical Recommendations for Seasonal Influenza Prevention and Control | COCA - Centers for Disease Control and Prevention | CDC (.gov)","headline":"2025 – 2026 Clinical Recommendations for Seasonal Influenza Prevention and Control | COCA - Centers for Disease Control ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQTk9kM0E0ZXVLRFRncE10UUE5ZEdHVzR3SnlwQnNUZmxrM04xUG1MM2ZjV3pxRDR2eWVLc0NiV0lyS2lHbXpwTzQ4VmlkN1ZpbU1LZGU4dy1ONjI3cExvb3hiMzIyRUhZYUd5Mlo2U2NDZlRTUnc3UnVVU0FILV9NMDVMQXh2SjI0cEhEX1ZqR2VnSmozVjJ0ZXU1VFlSMlNpeXR5YlQ3WUlRSHR2S25UemtuX1R0TXRiWHdDcWZ3?oc=5","date":"2025-10-07","type":"pipeline","source":"Fierce Pharma","summary":"CDC shakes up guidance for COVID, chickenpox shots based on ACIP recommendations - Fierce Pharma","headline":"CDC shakes up guidance for COVID, chickenpox shots based on ACIP recommendations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBRX1R0UFZpcHRhbjhSLVJDeEcyZGZDX2VPcmhzbmozbGhGR0lkTjhVQ1Z2LXdWRU1NdU0wRmprV3BwOXhuUW82RUJ1bGxOV2pvdDhOY3RSOV8tNHEyMW5RRTlZUWNqeXZJS3QzOXhBVVFSSE1m?oc=5","date":"2025-09-15","type":"pipeline","source":"Centers for Disease Control and Prevention | CDC (.gov)","summary":"Core Elements of Hospital Antibiotic Stewardship Programs - Centers for Disease Control and Prevention | CDC (.gov)","headline":"Core Elements of Hospital Antibiotic Stewardship Programs - Centers for Disease Control and Prevention | CDC (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNUERZdmpQdjFsRGRuNnljakpreTIydHFzaExrM3JXTmJ2M1dwSXJaVW9sTHZ2OGhXS0NmOUVyUVlWVWxmSjJpN19mVl9pcWt2Q3ZnYUtmeFlmSGV4YkFXNFlGby1yQzhVczBMcWhYTm5MNTlQN2pTRWVUVVY2SjZYOGhKd1BRMVh4MlVqOXNndXF4aW1UY251M1pLekZlMkE1WEY3OEtaMjJjcDZjY2pNUU43YUVuLUxaQk1jWVFEWmlMeXR0UVZB?oc=5","date":"2025-09-08","type":"pipeline","source":"Reuters","summary":"World Health Organization says US CDC needs to be protected - Reuters","headline":"World Health Organization says US CDC needs to be protected","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNYVhfc196eUpBRXJLdmFqaS1lLUt3dkhrNWZmbC1fMzFBdkVLRHd2djNKWkxZV3R0WlAzWW1sTmJOLUFlZmNPclNZLWluMXFtcVl6Sm1jQWd1TElmZlRLbWhKVlZOcWhvOWVWNXZhbnRmUFNscjBvLWV2UGxXM3pmRk5xbkV2S3o5dXE4ZUZsSE50WVB1a0hiZy16Q0o2QTFoZEU0NjlGZw?oc=5","date":"2025-08-28","type":"pipeline","source":"statnews.com","summary":"HHS secretary to testify at Senate hearing in wake of CDC shakeup - statnews.com","headline":"HHS secretary to testify at Senate hearing in wake of CDC shakeup","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQRTZFM3QxYUFGMUNTWkxVRXBOdHl2bHBCMDR6NzQzY25JT0xrOU1ha3JBcEhfNWxlakFkU3E4Z1BleHluSk43eFRzMzNjOEJqVU9QZW5jWklUZk1JY081OFc0RnlwTDNPRlhEZ2dySHFYWWdnYi1kVmVEN3Y2NGZreXphYTV4c0k2Wk1IX1o0VHlZOWll0gGaAUFVX3lxTE1qUXoxSU1BdXVrSWdBMksxWmtROC0tOEJiM2xERl9LXzhpek1ZTUwzREtKMlV1WGxVYWxIXzY2VkJENXVGVVlLNm5uMVdPNDZLQmRTb05KYUdHTXY1ZzE3M0FvTDU2TU9uZ0VuanJCaGMtNHJ0YkZuQWY1RWZSNHpsTVlXQmk3YzJWRXItbkhUaXpBTGVqeWloTHc?oc=5","date":"2025-08-11","type":"pipeline","source":"PBS","summary":"In CDC attack, man fired 180 shots, breaking 150 windows - PBS","headline":"In CDC attack, man fired 180 shots, breaking 150 windows","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-10","type":"pipeline","source":"PBS","summary":"CDC shooter believed COVID vaccine was harmful; union says misinformation put staff at risk - PBS","headline":"CDC shooter believed COVID vaccine was harmful; union says misinformation put staff at risk","sentiment":"neutral"}],"patents":[],"drugCount":49,"phaseCounts":{"phase_1":2,"marketed":36,"phase_3":10,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}